ReNeuron to Present at American Neurological Association Conference

Results to Form Part of Data Package to the US FDA In Support of Application to Commence Clinical Studies with ReN001-

Guildford,UK, 9 October 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it will present key pre-clinical efficacy data regarding its ReN001 stem cell therapy for stroke at the 131st Annual Meeting of the American Neurological Association in Chicago, US on October 8-11. The poster presentation will describe the positive and dose dependent effects of ReN001 in a pre-clinical rodent model of chronic stroke disability.

The results of the studies demonstrate that higher doses of clinical-grade ReN001 stem cells have the potential to reverse both the sensory and motor symptoms associated with stroke disability.
These results will form part of the Company’s data package in support of its impending application to the US FDA to commence initial clinical studies with ReN001.

More information about the conference may be found at

Notes to editors

ReNeuron is a leading, UK-based adult stem cell therapy business. The Group is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs.

ReNeuron has used its c-mycERTAM technology to generate genetically stable neural stem cell lines. This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation.

The Group’s lead stem cell therapy, ReN001 for chronic stroke disability, is in late pre-clinical development. The Company plans to file for approval to commence a Phase I clinical study in stroke by the end of 2006, with the study commencing as soon as possible thereafter. There are an estimated 50
million1 stroke survivors worldwide, approximately half of which are left with permanent disabilities. The healthcare costs of caring for these patients is estimated to amount to $45 billion2 in the US alone.

The Group has also generated pre-clinical efficacy data with its ReN005 stem cell therapy for Huntington’s disease, a genetic and fatal neurodegenerative disorder that affects around 1 in 10,000 people. This programme is in pre-clinical development.

In addition to its stroke and Huntington’s disease programmes, ReNeuron is developing stem cell therapies for Parkinson’s disease, Type 1 diabetes and diseases of the retina.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic areas � its ReNcellTM range of cell lines for use in drug
discovery applications in the pharmaceutical industry.

ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L, and its warrants are traded under the symbol RENW.L.

Further information on ReNeuron and its products can be found at

1. MOSES (Morbidity and mortality after stroke � Eprosartan vs nitrendipine for secondary prevention) study, Feb 2006
2. American Heart Association, Reporting Standards for Carotid Artery Angioplasty and Stent Placement, (Stroke, 2004; 35:e112).

Further information

Michael Hunt, Chief Executive Officer
John Sinden, Chief Scientific Officer
Tel: 44 (0)1483 302 560

Financial Dynamics
David Yates
Sarah Macleod
Tel: 44 (0)20 7831 3113